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Abstract
Somatic sequencing of cancers has produced new insight into tumorigenesis, tumor heterogeneity,
and disease progression, but the vast majority of genetic events identified are of indeterminate
clinical significance. Here we describe a NextGen sequencing approach to fully analyze 248
genes, including all those of known clinical significance in melanoma. This strategy features
solution capture of DNA followed by multiplexed, high-throughput sequencing, and was evaluated
in 31 melanoma cell lines and 18 tumor tissues from patients with metastatic melanoma.
Mutations in melanoma cell lines correlated with their sensitivity to corresponding small molecule
inhibitors, confirming, for example, lapatinib sensitivity in ERBB4 mutant lines and identifying a
novel activating mutation of BRAF. The latter event would not have been identified by clinical
sequencing and was associated with responsiveness to a BRAF kinase inhibitor. This approach
identified focal copy number changes of PTEN not found by standard methods, such as
comparative genomic hybridization (CGH). Actionable mutations were found in 89% of the tumor
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tissues analyzed, 56% of which would not be identified by standard-of-care approaches. This work
shows that targeted sequencing is an attractive approach for clinical use in melanoma.
INTRODUCTION
Clinical sequencing is already an essential part of melanoma treatment. Mutations in BRAF
and KIT have both high frequency (45% and 4% respectively (Hodis et al. 2012;
Krauthammer et al. 2012)) and clinical implications in melanoma (Flaherty et al. 2010; Kim
et al. 2008). Numerous other oncogenic mutations, including NRAS, and PIK3CA (18% and
3% of melanoma) could join the list of clinically actionable mutations, as ongoing clinical
trials progress (Ascierto et al. 2013). Additional therapies are also in development for driver
mutations that infrequently occur in melanoma (e.g. EZH2, RET, MEK1). Bringing these
therapies to bear on melanoma treatment will require rapid identification of tumor genotype
across a large, but defined subset of genes.
Recent whole exome sequencing studies have demonstrated substantial power and
sensitivity to discover new genes with significantly elevated mutation rates in melanoma.
Two such studies recently identified mutations of RAC1 and ARID2 as potential pathogenic
events in melanoma, among others, (Hodis et al. 2012; Krauthammer et al. 2012). Studies of
melanoma whole exomes, such as The Cancer Genome Atlas project, are powered to
identify genes mutated at even lower frequency. Whole exome analysis, however, suffers
from several drawbacks. Current methods cost ~$1,000 per sample for sequencing alone, as
well as additional costs of the capture methods. As exome sequencing is currently not
amenable to a high level of multi-sample pooling (multiplexing), it also incurs high cost in
both personnel and sequencing machine time. Perhaps most problematic, whole exome and
whole genome studies require computationally intensive bioinformatics analysis and data
storage consuming significant resources and specialist interpretation. This problem has been
described as “The $1,000 genome, [and] the $100,000 analysis” (Mardis 2010). Lastly, even
after a list of high confidence somatic mutations has been generated and annotated from
exomic data, the vast majority of such events will be of unknown significance.
More targeted approaches exist that can potentially alleviate the above issues. These options
include PCR-based resequencing or in-solution hybrid capture techniques with a more
focused target list. These approaches reduce costs and complexity at each stage. In the case
of PCR-based resequencing, reduction of the DNA sequence target to a much smaller scale
(< 1 megabase, Mb) permits more rapid sequencing and library generation, much higher
levels of multiplexing, and more simplified bioinformatics analysis. Hybrid capture
technologies, by comparison, retain a slower library generation process, but similarly allow
increased multiplexing for reduced sequencing requirements and per-sample costs. Hybrid
capture has two principal advantages over PCR-based approaches: it permits analysis of a
larger target (several MB), and, with concurrently sequenced matched normal control, can
be used to identify copy number events (Chinnaiyan & Palanisamy 2010; J. Li et al. 2012;
Sathirapongsasuti et al. 2011; Timmermann et al. 2010). The latter is of particular relevance
in melanoma, where deletion of tumor suppressor genes (e.g. CDKN2A, STK11 and PTEN)
plays a critical role in tumor pathogenesis.
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To develop a more cost effective sequencing pipeline we designed a targeted hybrid capture
approach for use in solid tumors including melanoma. This panel was designed to find all
known genetic events of clinical relevance for these cancers. The approach employed is
flexible and customizable to addition of new genes as their roles in cancer are better
characterized and clinical correlates are defined, and can make use of germline sequencing
information when available. Our captured list increased from 75 genes in version 1 to 248
genes in version 6. We first employed this assay on a panel of melanoma cell lines, and
identified novel genetic events that correlated with increased sensitivity to corresponding
small molecule inhibitors. We subsequently performed targeted exon capture sequencing in
18 tumor tissues obtained from patients with metastatic melanoma, including 4 tumor tissues
that were prospectively collected along with matched peripheral blood. Actionable events
detected in the prospective samples were disclosed to treating physicians after validation in a
clinical laboratory improvement amendment (CLIA) assay.
RESULTS
Targeted Capture and Sequencing Genotyping of Melanoma Cell Lines and Tumors
We performed target resequencing of genes with a reported role in melanoma and other
solid tumors by employing a multiplexed, in-solution capture in 31 melanoma cell lines and
18 patients. Variants were identified by comparison to matched normal specimens for the
prospective samples, or with the Unified Genotyper single sample mutation calling pipeline
(DePristo et al. 2011; McKenna et al. 2010) for the retrospectively collected tumor tissue
from patients with advanced melanoma and various melanoma cell lines (see methods).
Calls from retrospective samples without a matched normal were subjected to further
filtering to remove likely germline variants. This informatics approach was employed to
identify possible somatic variants with clinical relevance in melanoma treatment, biology,
and prognosis.
By applying version 1 (V1) of the assay in 31 melanoma cell lines, we identified 237 single
nucleotide variants (SNV) in coding regions of 59 genes (Table 1 and Supplementary Tables
1 and 2) and 15 insertion-deletion (indel) variants in 10 genes. Of the SNV calls, 64 were
synonymous (S) and 173 nonsynonymous (NS), including 9 resulting in a stop codon gain,
for a nonsynonymous-to-synonymous (NS:S) ratio of 2.70. This was higher than that seen in
previously reported whole-exome study of melanoma cell lines (Stark et al. 2012), likely due
to a higher degree of selection on this gene subset. Given our target sequence size of 446 kb
in 31 lines, this is an overall somatic mutation rate of 18 somatic mutations per Mb per line
(inner quartile range 8.97 to 26.9), consistent with the high mutation rate previously
described in melanoma (Hodis et al. 2012; Pleasance et al. 2010; Stark et al. 2012).
To demonstrate the clinical utility of our sequencing approach we subsequently used V2 of
the assay (Supplementary Table 1) to analyze 14 retrospectively collected melanoma tumor
tissues. For these samples, matched germ line DNA was not available, and therefore likely
germline events were filtered using bioinformatic approaches (see methods). By employing
this approach we identified 68 SNV and 4 indel variants in coding regions of 52 genes. Of
the SNVs, 50 were coding and 18 noncoding for a ratio of 2.78 and an average 25 somatic
mutations per Mb per tumor (inner quartile range 12.7 to 42.4).
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Finally, by employing V6 of the assay (Supplementary Table 1), we analyzed 4 tumors
prospectively collected from patients with metastatic melanoma for which a matched normal
tissue was available. SNVs were called by a more robust approach, relying on sequencing of
the matched normal to control for germline variants. We identified 105 coding variants, with
a range from 2 to 64 somatic mutations per patient.
Internal and External Validation
We previously sequenced NRAS, KIT, BRAF, MET and CDKN2A/B in the panel of 31
melanoma cell lines ((Shields et al. 2007) and not shown). These results were confirmed
using the V1 of our next generation sequencing (NGS) assay. A normal primary fibroblast
cell line processed in parallel with the melanoma cell lines resulted in only one synonymous
variant called as an SNV, validating that our approach has a low rate of false positives. In
the four melanomas with a matched normal, we identified seven mutations, out of which
five were successfully validated using a CLIA-certified assay. Although it is possible that
our failure to confirm these two mutations may reflect sequencing errors of our NGS assay,
more likely, we believe the observed discordance reflects lower sensitivity of the CLIA-
certified assay (e.g. Sanger sequencing), especially in the presence of stromal contamination
(Nollau & Wagener 1997). These results suggest the assay is highly accurate with regard to
the detection of SNVs in cell lines and primary tumors.
In comparison with published melanoma datasets (COSMIC (Forbes et al. 2011) and two
studies (Hodis et al. 2012; Krauthammer et al. 2012)), somatic single nucleotide mutation
frequencies and profiles were similar for both melanoma cell lines and tumors (Fig. 1A,B).
For example, BRAF and NRAS mutations were noted in 52% and 21% respectively of all
samples (cell lines and patient samples). Canonical BRAF V600E and NRAS Q61R
mutations were present at a range of estimated allele frequencies in patient derived samples
(from 16% to 91%). This suggests robust detection of mutations in the presence of
substantial aneuploidy or stromal contamination. In addition, single base pair mutations in
cell lines and unmatched tumor samples exhibited C → T mutation bias (Fig. 1C,D). This
mutation profile has been reported in whole genome (Pleasance et al. 2010) and exome
sequencing (Hodis et al. 2012; Krauthammer et al. 2012) in melanoma, suggesting common
ultraviolet light-induced mutagenesis. These data suggest targeted NextGen sequencing
yields mutation frequencies and spectrum that are similar to large-scale whole genome and
exome sequencing strategies.
Exemplary Events not Found by Standard Analyses
Apart from hot-spot mutations of RAS/RAF/KIT detected by standard molecular pathology
approaches, the assay was able to identify a diverse set of genetic aberrations not found
using standard clinical sequencing. For example a 5 codon in-frame deletion mutation of
BRAF in the Mel537 cell line was discovered (BRAF del486-491) (Fig. 2A). This mutation
exhibited remarkable structural similarity (Fig. 2B) to activating in-frame deletions of the
EGFR kinase found in non-small cell lung cancer (Jackman et al. 2006). Consistent with this
mutation being an activating event, this line co-clustered with NRAS and BRAF mutant
tumors, but not with RAS/RAF wildtype tumors, in an RNA expression analysis
(Supplementary Fig. 1). Additionally this line exhibited increased levels of phospho-ERK
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that decreased with treatment with a BRAF inhibitor, PLX-4032 (Fig. 2C,D), in contrast to
the paradoxical increase in phospho-ERK that occurs in NRAS mutant tumors (Fig. 2C,
VMM39, see also (Carnahan et al. 2010; Halaban et al. 2010; Heidorn et al. 2010)).
Compared to lines harboring the classical V600E BRAF mutation, Mel537 was
comparatively less sensitive to both BRAF (PLX-4032) and MEK inhibitors (trametinib or
GSK1120212 (Stones et al. 2013)) (Fig. 2C-F). This observation may be driven by altered
downstream signaling in the BRAF del486-491 mutant, altered binding of drug substrates, or
by additional mutations in the Mel537 cell line not related to the RAS-RAF-ERK signaling
cascade. These results suggest that the BRAF del486-491 mutation is a non-canonical
mechanism to activate ERK and downstream targets in melanoma, and is associated with
moderate sensitivity to BRAF and MEK inhibitors.
Consistent with a prior report (Prickett et al. 2009; Stark et al. 2012), we noted several
mutations in diverse regions (Fig. 3A) of the ERBB4 gene in melanoma cell lines and
tumors. Melanoma cell lines harboring mutations of this kinase exhibited a trend (p=0.1)
towards enhanced sensitivity to the EGFR-inhibitor, lapatinib, in accordance with prior
findings (Fig. 3B) (Prickett et al. 2009). While these mutations appear common (observed in
10% of melanoma primaries and cell lines assessed in this sample), the dispersion of these
mutations throughout the gene makes their identification difficult by classical (Sanger)
sequencing. Other potential clinically actionable events were observed in both melanoma
cell lines (Supplementary Table 2) and clinical samples (Table 2) and included previously
described as well as novel mutations in PIK3CA and KIT.
Tumor Suppressor Loss
In addition to detecting mutations in oncogenes, we employed our NextGen assay to detect
genetic aberration in tumor suppressor genes that play important roles in melanoma
progression (Dankort et al. 2009; Liu et al. 2012), overall prognosis (Nathanson et al. 2011),
and response to small molecule inhibitors (Trunzer et al. 2013). To estimate tumor
suppressor inactivation in the melanoma cell line panel, data from NextGen sequencing were
analyzed to identify complete deletion of targeted exons. For this analysis, we identified
exons with no sequencing coverage in a subset of melanoma cell lines with otherwise
substantial coverage (>30x) in other lines. These calls were validated by CGH array data
where available.
All NextGen-based deletion calls were consistent with CGH arrays, and vice-versa, with the
exception of highly focal deletions of PTEN noted in two melanoma cell lines that were
called in sequencing but were undetectable by CGH (Fig. 4A). These were regions with
complete loss of coverage of individual exons of PTEN in the WM2664 and SKMEL24
lines (Fig. 4B). These findings were in keeping with the total absence of PTEN protein
observed in these lines by ourselves and others ((Stahl et al. 2003) and not shown).
Melanoma cell lines with larger deletions spanning the PTEN gene were apparent as loss of
sequencing coverage of all exons, while the majority of lines showed intact PTEN genes
with coverage of all exons. When these genetic aberrations were combined with SNV/indel
calls, the observed rates of CDKN2A, PTEN and TP53 mutation were 44%, 29%, and 24%
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respectively (Fig. 4C), consistent with prior analyses of melanoma cell lines (Forbes et al.
2011; Stark et al. 2012) and TCGA (see e.g. cBioPortal (Cerami et al. 2012)).
Combined SNV and copy number analysis of NextGen sequencing yielded a high total rate
of less common tumor suppressor gene (TSG) mutations in our clinical samples as well
(Table 2). Mutations in APC, ATM, BRCA1, BRCA2, PTEN, RB1 or TET1 were seen in 10
out of 14 completed patients (71%) lacking matched normal. We additionally identified
copy number changes in both target and off-target regions by comparing tumor coverage to
that of the matched normal, where available. When restricting the analysis to captured
genes, two tumors had copy number changes reaching significance (adjusted p < 0.10).
These were in CCND2 (5.4 fold copy number vs. normal) and PTEN (0.3 fold copy number
vs. normal), and both are commonly mutated in melanoma (Forbes et al. 2011), TCGA
(cBioPortal (Cerami et al. 2012)). Collectively, our results show the ability of targeted
capture exome NGS to detect various genetic aberrations, both mutation and copy number
changes, in common as well as infrequently mutated genes, which may provide further
insights about their role in prognosis and treatment decisions.
Assessment of Clinical Actionability and Result Reporting
To assess the potential clinical applicability of this targeted sequencing approach, we
identified patients with somatic mutations that might influence clinical care (Table 2). These
mutations were associated with either a potential treatment (small molecule inhibitors) or
with use in prognosis and diagnosis (Table 3). Therapeutic indications were mutations
associated with sensitivity to agents i) approved for use in melanoma, ii) approved for use in
a different tumor type or iii) in human clinical trials for melanoma. Of the 18 patient-derived
tumors, 16 patients (89%) carried mutations that could influence treatment decisions,
including possible enrollment into a clinical trial. These included BRAF activating mutations
(V600E and D594E) as well as mutations in ALK, ERBB4, KIT, and PIK3CA. Even
excluding BRAF mutations found by standard clinical testing, 9 patients exhibited mutations
that could influence therapy. This ‘actionability’ rate is comparable to that recently reported
by another group in a large study of multiple cancer types including melanoma (Frampton et
al. 2013).
Patients with metastatic melanoma who consented to have their tumor sequenced for
actionable somatic mutations underwent NextGen sequencing using our assay as part of an
ongoing clinical trial (NCT01457196). Somatic mutations deemed clinically actionable by
the above criteria could be reported to a physician after validation using a CLIA-certified
assay. In the four melanomas analyzed, we found between 0 and 6 actionable mutations per
tumor (Table 3). One tumor had the BRAF V600E mutation alone. Two other tumors had
several mutations, including one in MAP3K1, recently reported to have tumor suppressor
activity in melanoma (Stark et al. 2012), as well as ERBB4 and PIK31R. Mutations in five
genes (ABL, BRAF, MET, PDGFRA, and PDGFRB, Table 2 underlined) from 3 patients
were confirmed by a CLIA-certified method and reported in the clinical record. These
results indicates that this low-cost, capture-based sequencing can be performed in clinical
real-time to provide actionable information beyond currently performed clinical sequencing.
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In this report, we describe the development and performance of a customized, capture-based
NextGen assay to identify somatic genetic aberrations, both mutations and copy number
changes, in genes associated with cancer development, progression, prognosis, and response
to treatment. Identification of such genetic aberrations may influence clinical care of patients
with melanoma and other cancers. This approach can be easily modified to include
additional genes whose role in cancer is being better established. Using this approach, we
demonstrated in a limited number of tumor tissues obtained from patients with advanced
melanoma that such patients harbor a high frequency of actionable genetic aberrations
beyond BRAF, NRAS and KIT. We observed actionable events both for oncogenes outside of
regions commonly subjected to sequencing in the current clinical setting (e.g. “non-
canonical” mutations of BRAF) and of druggable oncogenes not traditionally considered to
drive melanoma formation (e.g. PIK3CA and ERBB4). For three cases, events identified
using this approach were validated using CLIA-approved methods and reported to patients
and caregivers within the context of a clinical trial.
While whole exome/genome analyses have their merit for scientific discovery, we believe
that the use of highly targeted sequencing panels is presently the most cost-effective
approach for use in clinical decision-making. In addition to cost-efficacy, highly targeted
sequencing can produce greater depth of sequencing coverage over the target, allowing the
identification of mutations with relatively low minor allele frequency (<10%) within a
sample. This is essential for samples with stromal contamination, which is likely to be a
common feature of clinical samples, or in the presence of genetic heterogeneity within the
tumor. Such an approach will be valuable in upcoming clinical trials that attempt to: identify
in real-time patient subsets that may exhibit primary resistance to small molecule inhibitors
(Trunzer et al. 2013), understand the genetic patterns of resistance to small molecule
inhibitors (Nazarian et al. 2010; Shi et al. 2012), and provide guidance for rational treatment
combinations applicable only to select patient subgroups. This approach leverages the
information from large discovery-driven projects (Hodis et al. 2012; Krauthammer et al.
2012) and TCGA while allowing significantly reduced costs through multiplexing.
Additional multiplexing is likely to be possible as sequencing technologies continue to
advance. Of note, we have now extended the assay to formalin-fixed paraffin embedded
(FFPE) samples, allowing for greater utility in common clinical care. DNA quality from
FFPE in general is adequate for capture based NextGen sequencing, yielding results
comparable to those obtained using frozen material (not shown and (Frampton et al. 2013)).
Using this approach, we identified an unusual mutation (del486-491) in BRAF in a cell line
that would not be identified by standard-of-care approaches. Although we are not aware of a
prior identification of this BRAF mutation in melanoma, the del486-491 mutation has been
previously reported in an ovarian cell line (Hanrahan et al. 2012). The ability of this
mutation to lead to activation of ERK and its moderate sensitivity to BRAF and MEK
inhibitors suggests this mutation merits clinical assessment. We believe this mutation may
be more common than appreciated, having escaped prior identification because it is not in a
commonly analyzed exon (12 as opposed to 15 and 11) and is a 15 bp deletion, requiring
approaches dedicated toward identifying these events. Targeted sequencing successfully
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identified BRAF and NRAS mutations observed in melanoma, but also discovered more rare
events in these genes. This approach also readily identified canonical, activating mutations
of other druggable oncogenes, many of which are the target of ongoing clinical trials (e.g.
PIK3CA).
The ability to uncover many simultaneous mutations within a melanoma affords new
opportunities for multiple targeted therapies. However, the principles of such treatments
remain unclear. Which mutations, if any, should take priority for targeting, or should
multiple oncogenic mutations always be targeted with multiple therapies? Though it seems
likely that multiple therapies will more effectively target resistance pathways, as with dual
BRAF/MEK inhibition in melanoma, multiple pathway targeting has also lead to increased
toxicity (e.g. as seen with combinations of MEK and PI3K inhibitors). Most difficult is the
rarity of any one particular assemblage of mutations, given the number of possible mutations
involved. In the near term, the personalization of cancer therapy remains experimental.
Finally, capture offers a platform for determination of genetic aberrations in tumor
suppressors genes, allowing simultaneous assay of SNVs, indels, and copy loss in genes
such as ERBB4, STK11, RB1, CDKN2A, and PTEN. Inactivation of these genes is common
in melanoma, and likely will strongly affect tumor biology. For example, RB1/CDKN2a
status correlates with sensitivity to CDK4/6 inhibitors (Wiedemeyer et al. 2010), whereas
loss of ERBB4 is associated with lapatinib sensitivity (Figure 4 and ((Prickett et al. 2009)),
which is currently being tested in a clinical trial (NCT01264081). Our results identifying
microdeletions within the PTEN gene are of particular interest, since such events were not
detected by CGH and could play important roles in targeted therapy. Recent improvements
in bioinformatic techniques enabling comparison of patient germline to neoplastic tissue for
CNV detection will aid future analysis of targeted tumor suppressor sequencing in a clinical
setting. The ability to affordably and reliably assay TSG status could aid prognosis,
subtyping and therapy in melanoma.
METHODS
Clinical Material
Snap-frozen primary tumor tissues were obtained as part of institutional review board (IRB)-
approved protocols at the Lineberger Comprehensive Cancer Center and the University of
North Carolina. Samples from four prospective patients were collected under an ongoing
clinical trial LCCC1108 (NCT01457196), whereas samples from 14 retrospective patients
were collected under IRB#09-0989. For the four prospective patients, a matched normal
tissue (whole blood), was also acquired. DNA was isolated with the Puregene DNA
Purification Kit (Gentra Systems) or DNAeasy (QIAGEN).
Sequencing Library Preparation and Capture
Custom adapters were designed to match Illumina PE adapters with an additional 4
nucleotide ‘barcode’ sequence located internal to the first and second read sequencing
(Supplementary Fig. 2). Barcode sequences were designed to require errors in at least 2
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locations to be misidentified, allowing for error correction with the use of paired reads
tolerant to up to 3 errors.
Sample workflow is detailed in Supplementary Figure 3A. Libraries were constructed per
the SureSelect protocol (Agilent) with custom adapters replacing the Illumina PE adapters.
Samples were quantified by bioanalyzer prior to capture, and pooled in equimolar quantity
with 10 libraries to a pool in the case of cell lines and 8 libraries to a pool in the case of
melanoma tumor samples to a final quantity of 500ng. Four samples for which a matched
normal was available were prepared with the SureSelect XT library preparation kit (Agilent)
by manufacturer protocols. Capture and post capture amplification for all samples proceeded
by SureSelect protocol. Samples were sequenced on the GAII or HiSeq machine in a variety
of formats (see Supplementary Table 3).
Bioinformatics Analysis of Unmatched Samples
Bioinformatics workflow is detailed in Supplementary Figure 3B. Custom Java applications
were used to assign multiplex libraries to their source sample, after which samples were
mapped using the Burrows-Wheeler Aligner (Keniry & Parsons 2008) to the hg18 reference
genome. The Genome Analysis Toolkit GATK (version 1.0.5506)(H. Li & Durbin 2009)
was used for quality score recalibration, indel realignment, and SNV and indel calling. SNV
and indels were then annotated for appearance in prior 1,000 genomes (DePristo et al. 2011;
McKenna et al. 2010) and dbSNP version 130 (Consortium 2012) to filter likely germline
mutations and identify affected transcripts using the ANNOVAR tool (Sherry et al. 2001).
Mutations with any prior detection rate in 1,000 genomes samples as annotated by
ANNOVAR were ignored in further analysis, with exception of the NRAS Q61R mutation,
which appears in dbSNP 130, as it is a known oncogenic event. Analysis of duplicate reads
counts, base quality calls, and read mapping percentages were performed at appropriate
steps as quality control. One line sequenced, 1205LU, was proved to be murine in origin,
and was excluded from downstream analysis. Two cell lines believed to be distinct were
genetically identical (SKMEL78 and SKMEL88), and were treated as a single line in
analysis.
Bioinformatics Analysis of Matched Samples
Bioinformatics analysis of tumor samples for which DNA extracted from a same-patient
normal tissue was available followed a similar IRB-approved protocol, but somatic variants
were called using Varscan (Koboldt et al. 2009) and annotated using the ANNOVAR
utility(Wang et al. 2010). Coding somatic variants with “Moderate” or “High” predicted
effects were reported. For copy number analysis, each gene targeted to capture is tested for
significantly different coverage compared to a normal reference using the DESeq algorithm
(Anders & Huber 2010).
Gene Expression Microarray
Previously published gene expression microarray data sets (Carson et al. 2012) were filtered
for the top 10% most variable genes (standard deviation of log2 ratio of expression vs.
reference) and median centered by gene. Probe sets were clustered by unsupervised
hierarchical clustering using uncentered correlation as the similarity metric via the Gene
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Cluster 3.0 (Carson et al. 2012) tool and visualized with Java TreeView (de Hoon et al.
2004).
Array Based Identification of Copy Number Variation
For array-based determination of copy number in cell lines we used the Agilent 180K
SurePrint G3 Custom CGH+SNP arrays (catalog # G4884a). Calls were determined by
circular binary segmentation with the DNAcopy package through Bioconductor. Calls were
filtered for those with a log2 ratio < −0.5 and p value < 0.01. These were further analyzed
for deletions in APC, CDKN2A, MSH6, TP53, RB1, and PTEN tumor suppressors.
Sequencing Based Identification of Copy Number Variation in Cell Lines
Coordinated analysis of these same genes by sequencing utilized the clonality of cultured
cell lines to identify additional deletion events. Deletion regions of the genome were those
showing zero coverage by high-throughput sequencing reads. As coverage is expected to be
low except in regions of capture, we restricted our analysis to exons of APC, CDKN2A,
MSH6, TP53, RB1, and PTEN with average coverage > 30x in control cell lines. Genes with
zero coverage in a sample with no otherwise notable mutations were marked as deleted by
sequencing determined exon loss.
Chemosensitivity Assays
Cells were plated onto 96-well assay plates (Costar #3903) at different cell densities,
depending on each cell line’s growth rate, in 100 μl of media per well. Cells were then
treated with dilutions of drugs or vehicle (DMSO) in triplicate18 hours after plating. Drugs
used included Lapatinib (GlaxoSmithKline), PLX 4032 (Roche), and trametinib
(GSK1120212, GalaxoSmithKline). Cell viability was assessed at 72 hours after plating
using the CellTiter-Glo Luminenscent Cell Viability Assay (Promega) and a Synergy2
microplate reader (BioTek). Raw data was imported into GraphPad Prism 5.0 and IC50
calculated using non-linear regression analysis of the log inhibitor concentration versus
luminescence.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Gene sequencing is an essential part of treatment for metastatic melanoma, but current
clinical strategies are limited to a few exons of only two genes. Here, we develop a
scalable NextGen sequencing assay to identify point mutations and copy number events
affecting all actionable genes associated with advanced melanoma. Using this approach,
we identify actionable events in 90% of patients, which we disclose to caregivers after
validation using a CLIA–approved assay. Importantly, we find that over half of tumors
harbor actionable mutations that would not be detected by standard-of-care clinical
sequencing, including a novel activating BRAF mutation.
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Figure 1. Aggregate Analysis of Mutation Calls
(A) Co-occurrence of mutations in melanoma cell lines including SNVs, CNV calls from
SNP array, and both. (B) Co-occurrence of mutations in metastatic cutaneous melanoma
showing KIT mutations in BRAF and NRAS wild type lines. (C) Putative somatic mutation
rates in melanoma cell lines and (D) putative somatic mutations in tumors.
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Figure 2. Non-Frameshift BRAF Mutation Sensitive to PLX4032
(A) Mel537 cell line aggregate read depth and mapped reads show homozygous non-
frameshift deletion mutation in exon 12 of BRAF. (B) Structural alignment of inhibitor
bound BRAF structure (CYAN) to inhibitor bound EGFR (GREEN) showing structural
homology of the BRAF exon 12 deletion (RED) and know activating EGFR exon 19
deletions (PINK). (C) ERK and activated ERK (pERK) blots in serum-starved lines with and
without PLX4032 treatment. (D) PLX4032 sensitivity of SKMEL27 (BRAF V600E),
Mel537, and VMM39 (NRAS Q61R). (E) ERK and activated ERK (pERK) blots in serum-
starved lines with and without MEK inhibition by GSK112. (F) GSK112 sensitivity of
SKMEL27, Mel537 and VMM39.
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Figure 3. ERBB4 Mutation Predicts Lapatinib Sensitivity
(A) Previously reported mutations in ERBB4 (PINK) and in three cell lines (BLACK) span
multiple domains of the gene. (B) Lapatinib sensitivity in three ERBB4 mutant lines was
increased compared to ERBB3 wild type lines (p = 0.1).
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Figure 4. Sequencing Detects Focal Deletions at High Resolution
(A) CNV calls using SNP microarrays. (B) Sequencing coverage of PTEN exons in
WM2664, PMWK, SKMEL24 and UACC257 with very low coverage in a PTEN deletion
line (PMWK) as well as isolated exons in other lines (red arrowheads). (C) Aggregated
mutation rates in selected tumor suppressor genes in cell lines using CGH array and
sequencing.
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Table 1
Selected Mutations in Melanoma Cell Lines and Patients
Selected genes from melanoma cell lines and patient tumors with potential activating mutations.
Sample Gene Mutation Previously Observed?
Cell Line SKMEL100 KIT Y362F No
SBC12 PIK3CA K678E No
RPMI8322 KRAS G12V Yes
SKMEL78/88 HRAS G12V Yes
Patient Tumor RAM99-0621B KIT L255Q No
RAM00-0594B PIK3CA R88Q Yes
RAM99-0621B PIK3CA E545K Yes
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Table 3
Genes and Associated Clinical Action
Genes discovered in patient tumors with clinical actionability, along with the associated action and therapy.
Gene Category Action
ABL Approved Therapy Imatinib, Desatinib, Nilotinib, Ponatinib
ALK Approved Therapy Crizotinib
BRAF Approved Therapy Vemurafenib
ERBB4 Clinical Trials Lapatinib
KDR Approved Therapy and Clinical Trials Nonspecific kinase inhibition: Sunitinib, Sorafenib, Pazopenib
KIT Approved Therapy Desatinib
MET Approved Therapy Crizotinib, Carbozantinib
NOTCH4 Clinical Trials Gamma Secretase Inhibitors
NRAS Future Clinical Trial MEK/ERK inhibitors
PDGFRA Clinical Trials PDGFR inhibitors (e.g. Crenolanib)
PDGFRB Clinical Trials PDGFR inhibitors (e.g. Crenolanib)
PIK3CA Clinical Trials PI3K Inhibitors
PTEN Future Clinical Trial PI3K Inhibitors
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